Dow Jones
36 404,93 +157,06 (+0,43 %) Nasdaq
14 432,49 +28,51 (+0,20 %) Nikkei 225
32 791,80 +483,94 (+1,50 %) EUR/USD
1,0767 +0,0002 (+0,02 %) HANG SENG
16 201,49 -132,88 (-0,81 %) Bitcoin EUR
38 300,70 -2 440,77 (-5,99 %)
Sanofi (SNY)
Échanges après Bourse :
Sanofi
46, avenue de la Grande Arm e
Paris 75017
France
33 1 53 77 40 00
https://www.sanofi.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 91 573
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Paul Hudson | CEO & Director | 4,04M | S.O. | 1967 |
| Mr. Jean-Baptiste Chasseloup de Chatillon | Executive VP & CFO | S.O. | S.O. | 1965 |
| Ms. Madeleine Roach | Executive VP & Head of Business Operations | S.O. | S.O. | S.O. |
| Mr. Laurent Gilhodes | Principal Accounting Officer and Vice President of Corporate Accounting | S.O. | S.O. | S.O. |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care | S.O. | S.O. | S.O. |
| Eva Schaefer-Jansen | Head of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Dante Beccaria | Global Compliance Officer & VP | S.O. | S.O. | S.O. |
| Mr. Roy Papatheodorou | Executive VP & General Counsel | S.O. | S.O. | 1978 |
| Mr. Josep Catlla | Head of Communications | S.O. | S.O. | S.O. |
| Mr. Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | S.O. | S.O. | 1957 |
Description
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Sanofi en date du 1 décembre 2023 est 2. Les scores principaux sont Audit : 4; Société : 2; Droits des actionnaires : 6; Compensation : 2.
